Analysing Heterogeneity to Support Decision Making

Encyclopedia of Health Economics

Volumn , Issue , 2014, Pages 71-76

  Espinoza, M A ^a,b   Sculpher, M J ^c   Manca, A ^c   Basu, A ^d  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b INSTITUTO DE SALUD PÚBLICA DE CHILE   (Chile)

^c UNIVERSITY OF YORK   (United Kingdom)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Choice; Cost effectiveness analysis; Decision making; Economic evaluation; Health technology assessment; Heterogeneity; Individualized care; Potential outcomes; Preferences; Subgroup analysis; Variability

Indexed keywords

EID: 84920993777     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-375678-7.01420-6     Document Type: Chapter

References (19)

1. Basu A., Meltzer D. Value of information on preference heterogeneity and individualized care. Medical Decision Making 2007, 27(2):112-127.
2. Coyle D., Buxton M.J., O'Brien B.J. Stratified cost-effectiveness analysis: A framework for establishing efficient limited use criteria. Health Economics 2003, 12:421-427.
3. Nease R.F., Owens D.K. A method for estimating the cost-effectiveness of incorporating patient preferences into practice guidelines. Medical Decision Making 1994, 14:382-392.
4. Baron R.M., Kenny D.A. The moderator-mediator variable distinction in social psychological research: Conceptual, strategic and statistical considerations. Journal of Personality and Social Psychology 1986, 51:1173-1182.
5. Basu A. Economics of individualization in comparative effectiveness research and a basis for a patient-centered healthcare. Journal of Health Economics 2011, 30(3):549-559.
6. Decision modelling for health economic evaluation 2006, Oxford University Press, Gosport, Hampshire. A. Briggs, M.J. Sculpher, K. Claxton (Eds.).
7. Conti R., Veenstra D.L., Armstrong K., Lesko L.J., Grosse S.D. Personalized medicine and genomics: Challenges and opportunities in assessing effectiveness, cost-effectiveness, and future research priorities. Medical Decision-making 2010, 30:328-340.
8. Hamburg M., Collins F. The path to personalized medicine. New England Journal of Medicine 2010, 363:301-304.
9. Heckman J.J., Clements N., Smith J. Making the most out of programme evaluations and social experiments: Accounting for heterogeneity in program impacts. Review of Economic Studies 1997, 64:487-535.
10. Heckman J.J., Urzua S., Vytlacil E.J. Understanding instrumental variables in models with essential heterogeneity. Review of Economics and Statistics 2006, 88:389-432.
11. Kravitz R., Duan N., Braslow J. Evidence-based medicine, heterogeneity of treatment effects, and the trouble with averages. Milbank Q 2004, 82:661-687.
12. Manca A., Rice N., Sculpher M.J., Briggs A.H. Assessing generalisability by location in trial-based cost-effectiveness analysis: The use of multilevel models. Health Economics 2005, 14:471-485.
13. National Institute for Health and Clinical Excellence. (2005). Social value judgments: Principles for the development of NICE guidelines, 2nd ed. London: NICE. Available at: (accessed 30.05.12). http://www.nice.org.uk.
14. National Institute for Health and Clinical Excellence. (2008). Guide to the Methodsof Technology Appraisal. Available at: (accessed 30.05.12). http://www.nice.org.uk.
15. Nease R.F., Kneeland T., O'Connor G.T., et al. Variation in patient utilities for outcomes of the management of chronic stable angina. Journal of the American Medical Association 1995, 273:1185-1190.
16. Oxman A., Guyatt G. A consumer's guide to subgroup analyses. Annals of Internal Medicine 1992, 116:78-84.
17. Sculpher M.J. Subgroups and heterogeneity in cost-effectiveness analysis. Pharmacoeconomics 2008, 26:799-806.
18. Sculpher M., Pang F., Manca A., et al. Generalisability in economic evaluation studies in healthcare: A review and case studies. Health Technology Assessment 2004, 8. 49.
19. Stinnett A.A., Mullahy J. Net health benefits: A new framework for the analysis of uncertainty in cost-effectiveness analysis. Medical Decision-making 1998, 18:S68-S80.